RASA1 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P20936 |
---|---|
Clone Names | 101008186 |
Gene ID | 5921 |
---|---|
Other Names | Ras GTPase-activating protein 1, GAP, GTPase-activating protein, RasGAP, Ras p21 protein activator, p120GAP, RASA1, GAP, RASA |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | RASA1 |
---|---|
Synonyms | GAP, RASA |
Function | Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1. |
Cellular Location | Cytoplasm. |
Tissue Location | In placental villi, detected only in the trophoblast layer (cytotrophoblast and syncytiotrophoblast). Not detected in stromal, endothelial or Hofbauer cells (at protein level) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is located in thecytoplasm and is part of the GAP1 family of GTPase-activatingproteins. The gene product stimulates the GTPase activity of normalRAS p21 but not its oncogenic counterpart. Acting as a suppressorof RAS function, the protein enhances the weak intrinsic GTPaseactivity of RAS proteins resulting in the inactive GDP-bound formof RAS, thereby allowing control of cellular proliferation anddifferentiation. Mutations leading to changes in the binding sitesof either protein are associated with basal cell carcinomas.Alternative splicing results in two isoforms where the shorterisoform, lacking the N-terminal hydrophobic region but retainingthe same activity, appears to be abundantly expressed in placentalbut not adult tissues.
References
Hemerly, J.P., et al. Eur. J. Endocrinol. 163(5):747-755(2010)Wiemels, J.L., et al. Blood Cells Mol. Dis. 45(3):186-191(2010)Bachas, C., et al. Blood 116(15):2752-2758(2010)Oinuma, I., et al. J. Biol. Chem. 285(36):28200-28209(2010)Anand, S., et al. Nat. Med. 16(8):909-914(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.